When exposed to a foreign agent, such as an immunogenic protein, B cells in lymphoid organs undergo germinal center reactions. The image on the left is an immunized mouse spleen with activated B cells (brown) that produce antibodies. At right, top: a scanning electron micrograph of porous synthetic immune organs that enable rapid proliferation and activation of B cells into antibody-producing cells. At right, bottom: primary B cell viability and distribution is visible 24 hours following encapsulation procedure. Singh Lab
Cornell engineers have created a functional, synthetic immune organ that produces antibodies and can be controlled in the lab, completely separate from a living organism. The engineered organ has implications for everything from rapid production of immune therapies to new frontiers in cancer or infectious disease research.
The immune organoid was created in the lab of Ankur Singh, assistant professor of mechanical and aerospace engineering, who applies engineering principles to the study and manipulation of the human immune system. The work was published online June 3 in Biomaterials and will appear later in print.
The synthetic organ is bio-inspired by secondary immune organs like the lymph node or spleen. It is made from gelatin-based biomaterials reinforced with nanoparticles and seeded with cells, and it mimics the anatomical microenvironment of lymphoid tissue. Like a real organ, the organoid converts B cells – which make antibodies that respond to infectious invaders – into germinal centers, which are clusters of B cells that activate, mature and mutate their antibody genes when the body is under attack. Germinal centers are a sign of infection and are not present in healthy immune organs.
The engineers have demonstrated how they can control this immune response in the organ and tune how quickly the B cells proliferate, get activated and change their antibody types. According to their paper, their 3-D organ outperforms existing 2-D cultures and can produce activated B cells up to 100 times faster.
The immune organ, made of a hydrogel, is a soft, nanocomposite biomaterial. The engineers reinforced the material with silicate nanoparticles to keep the structure from melting at the physiologically relevant temperature of 98.6 degrees.
The organ could lead to increased understanding of B cell functions, an area of study that typically relies on animal models to observe how the cells develop and mature.
What’s more, Singh said, the organ could be used to study specific infections and how the body produces antibodies to fight those infections – from Ebola to HIV.
“You can use our system to force the production of immunotherapeutics at much faster rates,” he said. Such a system also could be used to test toxic chemicals and environmental factors that contribute to infections or organ malfunctions.
Read more: Engineers’ synthetic immune organ produces antibodies
The Latest on: Immune therapies
via Google News
The Latest on: Immune therapies
- Ask the Doctors: Lupus treatment often requires many medicationson March 2, 2021 at 10:00 pm
"There are several forms of the disease, but the most common is systemic lupus, which can affect the joints, skin and certain internal organs, including the heart and kidneys." ...
- Children with MIS-C have highly activated immune systems, study findson March 2, 2021 at 5:44 pm
Taking the first deep dive into how the immune system is behaving in patients with multisystem inflammatory syndrome in children (MIS-C), researchers at Children's Hospital of Philadelphia and the ...
- Psoriasis Pipeline Insight 2021 | Latest Advancements in Clinical Trials to Improve Treatmenton March 2, 2021 at 5:32 pm
DelveInsight’s “Psoriasis Pipeline Insight'' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscapes. It comprises Psoriasis pipeline ...
- Sequential administration of immunotherapy and targeted therapy prolongs anti-tumor responseson March 2, 2021 at 5:08 pm
Advanced melanoma is one of the deadliest types of cancer, with a 5-year survival rate of only 27% for patients with distant metastases.
- COVID-19 can derange the immune system in complex ways, research shows. Here's how.on March 2, 2021 at 1:22 pm
Researchers are testing treatments to overcome autoimmune reactions that begin when the body’s defenses respond to the coronavirus.
- Sequential treatment with immunotherapy and checkpoint inhibitors prolongs anti-tumor activityon March 2, 2021 at 9:00 am
Advanced melanoma is one of the deadliest types of cancer, with a 5-year survival rate of only 27% for patients with distant metastases. Recent advances in targeted therapies and immunotherapies have ...
- Key steps discovered in production of critical immune cellon March 2, 2021 at 5:07 am
WEHI researchers have uncovered a process cells use to fight off infection and cancer that could pave the way for precision cancer immunotherapy treatment.
- Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer | npj Breast Canceron March 2, 2021 at 4:38 am
We show that treatment with the FDA-approved anti-parasitic drug ivermectin induces immunogenic cancer cell death (ICD) and robust T cell infiltration into breast tumors. As an allosteric modulator of ...
- IN8bio Presents Gamma-Delta T Cells as Cancer Therapeutics at the ESMO Targeted Anticancer Therapies Virtual Conference 2021on March 2, 2021 at 4:07 am
IN8bio, Inc. (“IN8bio” or the “Company”), a clinical-stage biotechnology company focused on developing innovative gamma-delta T cell therapies, announced a presentation on the scientific rationale and ...
- Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression | Blood Cancer Journalon March 1, 2021 at 8:29 am
Immunotherapy has shown efficacy in relapsed multiple myeloma (MM). However, these therapies may depend on a functional tumor immune microenvironment (iTME) for their efficacy. Characterizing the ...
via Bing News
